目的 分析儿童急性淋巴细胞白血病（acute lymphoblastic leukemia, ALL）经中国儿童肿瘤协作组急性淋巴细胞白血病2015方案（Chinese Children's Cancer Group ALL-2015 protocol, CCCG-ALL-2015）治疗后的累积复发率（cumulative incidence of relapse, CIR），并探讨影响复发的危险因素。 方法 回顾性分析2015年1月—2019年12月接受CCCG-ALL-2015方案治疗的852例患儿的临床资料，计算CIR并分析影响儿童急性B淋巴细胞白血病（B-ALL）复发的危险因素。 结果 852例ALL患儿中，146例（17.1%）发生复发，8年CIR为（19.8±1.6）%。B-ALL与急性T淋巴细胞白血病患儿的8年CIR比较差异无统计学意义（P>0.05）。146例复发患儿中，复发时间主要集中于极早期（62例，42.5%）和早期（46例，31.5%），极早期单纯骨髓复发42例（28.8%），早期单纯骨髓复发27例（18.5%）。Cox比例风险回归模型分析显示，融合基因MLLr阳性（HR=4.177，95%CI：2.086~8.364，P<0.001）和第46天微小残留病≥0.01%（HR=2.013，95%CI：1.163~3.483，P=0.012）是B-ALL患儿经CCCG-ALL-2015方案治疗后复发的危险因素。 结论 儿童ALL经CCCG-ALL-2015方案治疗后仍有较高的复发率，以极早期和早期单纯骨髓复发常见；第46天微小残留病≥0.01%、融合基因MLLr阳性与B-ALL复发密切相关。
Abstract
Objective To investigate the cumulative incidence of recurrence (CIR) in children with acute lymphoblastic leukemia (ALL) after treatment with the Chinese Children's Cancer Group ALL-2015 (CCCG-ALL-2015) protocol and the risk factors for recurrence. Methods A retrospective analysis was conducted on the clinical data of 852 children who were treated with the CCCG-ALL-2015 protocol from January 2015 to December 2019. CIR was calculated, and the risk factors for the recurrence of B-lineage acute lymphoblastic leukemia (B-ALL) were analyzed. Results Among the 852 children with ALL, 146 (17.1%) experienced recurrence, with an 8-year CIR of 19.8%±1.6%. There was no significant difference in 8-year CIR between the B-ALL group and the acute T lymphocyte leukemia group (P>0.05). For the 146 children with recurrence, recurrence was mainly observed in the very early stage (n=62, 42.5%) and the early stage (n=46, 31.5%), and there were 42 children with bone marrow recurrence alone (28.8%) in the very early stage and 27 children with bone marrow recurrence alone (18.5%) in the early stage. The Cox proportional-hazards regression model analysis showed that positive MLLr fusion gene (HR=4.177, 95%CI: 2.086-8.364, P<0.001) and minimal residual disease≥0.01% on day 46 (HR=2.013, 95%CI: 1.163-3.483, P=0.012) were independent risk factors for recurrence in children with B-ALL after treatment with the CCCG-ALL-2015 protocol. Conclusions There is still a relatively high recurrence rate in children with ALL after treatment with the CCCG-ALL-2015 protocol, mainly bone marrow recurrence alone in the very early stage and the early stage, and minimal residual disease≥0.01% on day 46 and positive MLLr fusion gene are closely associated with the recurrence of B-ALL.
关键词
急性淋巴细胞白血病 /
中国儿童肿瘤协作组急性淋巴细胞白血病2015方案 /
复发 /
危险因素 /
儿童
Key words
Acute lymphoblastic leukemia /
Chinese Children's Cancer Group ALL-2015 protocol /
Recurrence /
Risk factor /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Pui CH, Tang JY, Yang JJ, et al. International collaboration to save children with acute lymphoblastic leukemia[J]. J Glob Oncol, 2019, 5: 1-2. PMID: 31045474. PMCID: PMC6550034. DOI: 10.1200/JGO.19.00010.
2 Sunamak E?, ?zdemir N, Koka A, et al. Comparison of outcomes of children with acute lymphoblastic leukemia treated with BMF protocol across 2 decades[J]. Pediatr Hematol Oncol, 2021, 38(2): 134-146. PMID: 33170046. DOI: 10.1080/08880018.2020.1825573.
3 Oskarsson T, S?derh?ll S, Arvidson J, et al. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome[J]. Haematologica, 2016, 101(1): 68-76. PMID: 26494838. PMCID: PMC4697893. DOI: 10.3324/haematol.2015.131680.
4 中国抗癌协会小儿肿瘤专业委员会急性淋巴细胞白血病2015多中心研究协作组. CCCG-ALL-2015方案多中心临床报告[J]. 中华儿科杂志, 2022, 60(10): 1002-1010. PMID: 36207846. DOI: 10.3760/cma.j.cn112140-20220719-00895.
5 Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population[J]. Blood, 2020, 136(16): 1803-1812. PMID: 32589723. DOI: 10.1182/blood.2019004043.
6 Lauten M, M?ricke A, Beier R, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia[J]. Haematologica, 2012, 97(7): 1048-1056. PMID: 22271901. PMCID: PMC3396677. DOI: 10.3324/haematol.2011.047613.
7 Tang J, Yu J, Cai J, et al. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation[J]. Blood, 2021, 138(4): 331-343. PMID: 33684941. PMCID: PMC8323972. DOI: 10.1182/blood.2020010438.
8 Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia[J]. Lancet Oncol, 2019, 20(3): e142-e154. PMID: 30842058. PMCID: PMC9233195. DOI: 10.1016/S1470-2045(19)30031-2.
9 Schrappe M, Bleckmann K, Zimmermann M, et al. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000)[J]. J Clin Oncol, 2018, 36(3): 244-253. PMID: 29148893. DOI: 10.1200/JCO.2017.74.4946.
10 Pieters R, de Groot-Kruseman H, Van der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group[J]. J Clin Oncol, 2016, 34(22): 2591-2601. PMID: 27269950. DOI: 10.1200/JCO.2015.64.6364.
11 Ceppi F, Cazzaniga G, Colombini A, et al. Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention[J]. Expert Rev Hematol, 2015, 8(1): 57-70. PMID: 25367188. DOI: 10.1586/17474086.2015.978281.
12 Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts[J]. Haematologica, 2013, 98(11): 1702-1710. PMID: 23716539. PMCID: PMC3815170. DOI: 10.3324/haematol.2012.080432.
13 Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study[J]. Blood, 2010, 115(16): 3206-3214. PMID: 20154213. DOI: 10.1182/blood-2009-10-248146.
14 Marjerrison S, Antillon F, Fu L, et al. Outcome of children treated for relapsed acute lymphoblastic leukemia in Central America[J]. Cancer, 2013, 119(6): 1277-1283. PMID: 23165914. DOI: 10.1002/cncr.27846.
15 Jaime-Pérez JC, Pinzón-Uresti MA, Jiménez-Castillo RA, et al. Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor[J]. Hematology, 2018, 23(1): 1-9. PMID: 28580844. DOI: 10.1080/10245332.2017.1333294.
16 Zhang R, Zhu H, Yuan Y, et al. Risk factors for relapse of childhood B cell acute lymphoblastic leukemia[J]. Med Sci Monit, 2020, 26: e923271. PMID: 32619211. PMCID: PMC7353297. DOI: 10.12659/MSM.923271.
17 Chu J, Cai H, Cai J, et al. Prognostic significance of steroid response in pediatric acute lymphoblastic leukemia: the CCCG-ALL-2015 study[J]. Front Oncol, 2022, 12: 1062065. PMID: 36624786. PMCID: PMC9824631. DOI: 10.3389/fonc.2022.1062065.
18 El Chaer F, Keng M, Ballen KK. MLL-rearranged acute lymphoblastic leukemia[J]. Curr Hematol Malig Rep, 2020, 15(2): 83-89. PMID: 32350732. DOI: 10.1007/s11899-020-00582-5.
19 Conter V, Valsecchi MG, Parasole R, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study[J]. Blood, 2014, 123(10): 1470-1478. PMID: 24415536. DOI: 10.1182/blood-2013-10-532598.
20 Ampatzidou M, Papadhimitriou SI, Paterakis G, et al. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): the spectrum of clonal heterogeneity and its impact on prognosis[J]. Cancer Genet, 2018, 224-225: 1-11. PMID: 29778230. DOI: 10.1016/j.cancergen.2018.03.001.
21 Ford AM, Fasching K, Panzer-Grümayer ER, et al. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes[J]. Blood, 2001, 98(3): 558-564. PMID: 11468150. DOI: 10.1182/blood.v98.3.558.
22 Nú?ez-Enríquez JC, Mejía-Aranguré JM. Molecular biology and childhood leukemia: E2A-PBX1 and central nervous system relapse[J]. Rev Med Inst Mex Seguro Soc, 2015, 53 Suppl 3: S236-S239. PMID: 26509298.
23 Shen S, Chen X, Cai J, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial[J]. JAMA Oncol, 2020, 6(3): 358-366. PMID: 31944221. PMCID: PMC6990720. DOI: 10.1001/jamaoncol.2019.5868.
24 Li SQ, Fan QZ, Xu LP, et al. Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL[J]. Front Oncol, 2020, 10: 320. PMID: 32257948. PMCID: PMC7089930. DOI: 10.3389/fonc.2020.00320.
25 Vrooman LM, Blonquist TM, Harris MH, et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001[J]. Blood Adv, 2018, 2(12): 1449-1458. PMID: 29941458. PMCID: PMC6020806. DOI: 10.1182/bloodadvances.2018016584.
26 Pui CH, Pei D, Raimondi SC, et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy[J]. Leukemia, 2017, 31(2): 333-339. PMID: 27560110. PMCID:PMC528.8281. DOI: 10.1038/leu.2016.234.
27 Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia[J]. Br J Haematol, 2013, 162(5): 606-620. PMID: 23808872. DOI: 10.1111/bjh.12442.
PDF(592 KB)
